MedTrace Logo

Validation of HepaFat-Scan for Noninvasive Measurement of Steatosis in Youth

NCT02461212 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-04-10

No results posted yet for this study

Summary

The purpose of this study is to see if the HepaFat-Scan (a special sequence of images done in a MRI) can accurately detect the amount of fat in the liver.

Conditions

  • Non-alcoholic Fatty Liver Disease

Interventions

PROCEDURE

Magnetic Resonance Imaging (MRI)

A MRI scan which will include magnetic resonance spectroscopy (MRS) of the liver to determine hepatic triglyceride content, a hepafat scan to measure volume fraction of fat in liver tissue, and a MRI for detection of liver fibrosis. The scan will last approximately 15 minutes.

Sponsors & Collaborators

  • Resonance Health

    collaborator INDUSTRY

  • Emory University

    lead OTHER

Principal Investigators

  • Miriam B Vos, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-01
Primary Completion
2017-03-17
Completion
2017-03-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02461212 on ClinicalTrials.gov